Introduction {#S1}
============

It has been well documented that NAD^+^ declines in many tissues during aging, including skeletal muscle, liver, adipose tissue, brain, pancreas, spleen, heart, kidney, and lung, contributing to the development of various age-associated pathophysiologies ^[@R1]--[@R4]^. This phenomenon is caused, at least in part, by two molecular events: the age-associated decrease in NAD^+^ biosynthesis mediated by nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting NAD^+^ biosynthetic enzyme in mammals ^[@R5]^, and the age-associated increase in NAD^+^ consumption mediated by NAD^+^-consuming enzymes, such as poly-ADP-ribose polymerases ^[@R6]^ and CD38 ^[@R7]^. In mammalian NAD^+^ biosynthesis, nicotinamide is a predominant precursor, and NAMPT catalyzes the conversion of nicotinamide and 5'-phosphoribose pyrophosphate into nicotinamide mononucleotide (NMN), a key NAD^+^ intermediate ^[@R8],[@R9]^. NMN is also synthesized from nicotinamide riboside (NR), another NAD^+^ intermediate, by NR kinases, NRK1 and 2 ^[@R10]^. NMN, together with ATP, is then converted into NAD^+^ by NMN adenylyltransferases, NMNAT1--3. A number of studies have reported that NMN conveys remarkable effects of improving disease conditions and mitigating age-associated physiological decline ^[@R5],[@R11]--[@R18]^. For example, NMN treatment is able to restore glucose-stimulated insulin secretion in aged C57BL/6 mice and some genetic mouse models that show reduced insulin-secreting capability ^[@R19],[@R20]^. NMN also enhances insulin sensitivity and secretion in mouse models of diet- and age-induced type 2 diabetes or obesity ^[@R5],[@R11]^. NMN has also been shown to prevent ischemia/reperfusion injury in the heart ^[@R18]^. In addition, NMN maintains the neural stem/progenitor cell population in the aged hippocampus, improves mitochondrial function in aged skeletal muscle, and reverses arterial dysfunction in aged mice ^[@R12],[@R13],[@R16]^. In rodent models of Alzheimer's disease, NMN is able to protect mitochondrial and cognitive functions ^[@R14],[@R17]^. We have also demonstrated previously that NMN effectively mitigates age-associated physiological decline in regular chow-fed wild-type mice ^[@R15]^. Collectively, these findings strongly suggest that NMN is a critical endogenous compound for NAD^+^ biosynthesis and can be used as an efficient therapeutic and in preventive intervention against many age-associated disease conditions.

We have previously shown that NMN is absorbed from the gut into blood circulation within 2--3 min and transported into tissues within 10--30 min ^[@R5],[@R15]^. NMN is then immediately utilized for NAD^+^ biosynthesis, significantly increasing NAD^+^ content in tissues over 60 min. This fast pharmacokinetics has recently been confirmed by using doubly labeled isotopic NMN (C13-D-NMN), showing its rapid absorption and conversion to NAD^+^ in peripheral tissues ^[@R15]^. On the other hand, it has also been proposed that NMN is converted extracellularly to NR, which is transported into cells and reconverted to NMN ^[@R21]^. Recent studies, however, have shown that the analyses of *in vivo* kinetics of these NAD^+^ intermediates are affected by differences in sample collection and extraction methodologies ^[@R22],[@R23]^ (also see the [Methods section](#S8){ref-type="sec"}). Therefore, it is critical to understand the mechanism by which NMN or NR is transported into cells or tissues. The fast pharmacokinetics of NMN led us to the hypothesis that there is an effective transporter that facilitates the direct uptake of NMN into the gut and other organs. Thus, we set out to identify this presumed NMN transporter in mammals.

Results {#S2}
=======

Identification of a NMN transporter {#S3}
-----------------------------------

In our previous studies, we noticed that when NAMPT-mediated NAD^+^ biosynthesis was inhibited by FK866, a potent NAMPT inhibitor, in various types of primary cells, co-administration of NMN always produced higher NAD^+^ increases, compared to those that NMN induces in the absence of FK866 ^[@R5],[@R16],[@R20]^. Thus, we hypothesized that the expression of a presumed NMN transporter might be upregulated when NAD^+^ levels decrease. Based on this hypothesis, we conducted gene expression profiling in FK866-treated primary mouse hepatocytes, pancreatic islets, and hippocampal neurospheres, searching for genes commonly upregulated in these three primary cultures. We focused our searches to genes that encode transporters or transmembrane proteins and found only one gene that fitted these criteria but whose function was unknown. This gene, *Slc12a8*, exhibited 2.06, 1.69, and 4.91 for Z ratio in primary hepatocytes, islets, and neurospheres, respectively ([Fig. 1a](#F1){ref-type="fig"}). The *Slc12a8* gene belongs to the SLC12 gene family of the electroneutral cation-chloride-coupled cotransporters, and the function of the protein encoded by this gene remains unknown ^[@R24]^. Close homologs exist in mouse, human, zebrafish, *Drosophila*, and *C. elegans* ([Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). Although amino acid sequences are significantly diverged, the predicted ten membrane-spanning domains are conserved throughout these Slc12a8 homologs ([Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}). *Slc12a8* is highly expressed in the small intestine and pancreas and moderately in the liver and white adipose tissue ([Fig. 1b](#F1){ref-type="fig"}). We confirmed that *Slc12a8* expression was induced significantly in mouse primary hepatocytes, mouse NIH3T3 fibroblasts, and *ex vivo* explants of jejunum and ileum when NAD^+^ was reduced by treatment with FK866, whereas this induction was suppressed when NAD^+^ was restored by co-administration of FK866 and NMN ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Figs. 1c-d](#SD1){ref-type="supplementary-material"}).

To begin to examine whether the *Slc12a8* gene encodes the NMN transporter, we first determined the kinetics of NMN uptake in mouse primary hepatocytes. To inhibit the extracellular degradation of NMN to NR by CD73, the uptake of NR into cells through nucleoside transporters, and the intracellular NMN synthesis by NAMPT, we used AOPCP (adenosine-5′-\[α, β-methylene\]diphosphate), dipyridamole, and FK866, respectively. AOPCP inhibits 5'-nucleotidase activity by 97% ([Supplementary Fig. 1f](#SD1){ref-type="supplementary-material"}). A cocktail of these inhibitors did not affect cell viability up to 30 min ([Supplementary Fig. 1e](#SD1){ref-type="supplementary-material"}). In the presence of these inhibitors, we added 100 μM NMN and found that intracellular NMN levels significantly increased at 1 min time point compared to the control in mouse primary hepatocytes ([Fig. 1d](#F1){ref-type="fig"}). In this condition using the same inhibitors and 100 μM NMN, we knocked down *Slc12a8* and *Nrk1*, a major NR kinase that converts NR to NMN intracellularly ^[@R10]^, and examined the uptake of NMN at 1 min time point in primary hepatocytes. The knockdown (KD) efficiencies for both genes are approximately 80% ([Fig. 1e](#F1){ref-type="fig"}). Interestingly, the fast uptake of NMN was completely abrogated in *Slc12a8*-KD hepatocytes, whereas no significant reduction in NMN uptake was observed in *Nrk1*-KD hepatocytes ([Fig. 1f](#F1){ref-type="fig"}), suggesting that *Slc12a8* is necessary for the fast uptake of NMN in primary hepatocytes, and the observed increase in intracellular NMN is not due to the conversion of NR or nicotinamide into NMN.

Biochemical features of the Slc12a8 protein {#S4}
-------------------------------------------

Next, we overexpressed the full-length mouse *Slc12a8* cDNA in mouse NIH3T3 cells. We chose this cell line because it does not have any detectable extracellular activities of CD73 (converting NMN to NR) and CD38 (degrading NMN to nicotinamide and phosphoribose) and also has very weak NMN uptake activity (see [Fig. 2b](#F2){ref-type="fig"}). The observed molecular weight of the full-length Slc12a8 protein is \~90 kDa, which was also confirmed with N- and C-terminally FLAG-tagged Slc12a8 proteins ([Supplementary Fig. 2a](#SD1){ref-type="supplementary-material"}). Slc12a8 protein levels were significantly increased \~2.2-fold in *Slc12a8*-overexpressing NIH3T3 (Slc12a8-OE) cells ([Fig. 2a](#F2){ref-type="fig"}). We then determined the kinetics of NMN uptake using ^3^H-labeled NMN in Slc12a8-OE and control cells. The uptake of ^3^H-NMN was significantly enhanced at 3 and 5 min time points in Slc12a8-OE cells, compared to control cells ([Fig. 2b](#F2){ref-type="fig"}). Using these Slc12a8-OE cells, we determined the Michaelis-Menten parameters for the Slc12a8 protein. The *K*~*m*~ and the *V*~*max*~ for NMN were calculated to be 34.1 ± 8.3 μM and 11.5 ± 1.2 pmol/min/mg, respectively ([Fig. 2c](#F2){ref-type="fig"}). Notably, this *K*~*m*~ is consistent with a detected range of NMN concentrations in mouse plasma and erythrocytes ^[@R20],[@R25],[@R26]^. To further analyze the specificity of Slc12a8, we produced proteoliposomes by combining the membrane fractions of Slc12a8-OE or control NIH3T3 cells with the phospholipid bilayers derived from deproteinized erythrocyte plasma membrane. Slc12a8-OE-derived proteoliposomes incorporated significantly higher (\~2-fold) levels of ^3^H-NMN than those in control-derived proteoliposomes ([Supplementary Fig. 2b](#SD1){ref-type="supplementary-material"}). Using these Slc12a8-OE proteoliposomes, we examined whether the uptake of ^3^H-NMN into proteoliposomes would be competed by excess amounts of various cold NAD^+^-related compounds. 150 μM of cold NMN showed complete competition against ^3^H-NMN uptake, whereas NAD^+^, AMP, nicotinic acid mononucleotide (NaMN), and nicotinamide showed minimal or negligible competition at the same concentration ([Fig. 2d](#F2){ref-type="fig"}). We confirmed that NaMN, a structurally very similar compound to NMN, was not transported into Slc12a8-OE proteoliposomes ([Supplementary Fig. 2c](#SD1){ref-type="supplementary-material"}). Interestingly, 150 μM NR exhibited \~70% displacement ([Fig. 2d](#F2){ref-type="fig"}), and therefore, we further determined IC~50~ concentrations for NMN and NR, using the proteoliposome system. The IC~50~ for NMN was 22.8 ± 3.6 μM, whereas the IC~50~ for NR was 77.4 ± 10.8 μM ([Fig. 2e](#F2){ref-type="fig"}). This result suggests that the Slc12a8 protein is specific primarily to NMN under physiological conditions because NR levels have not been shown to reach such high concentrations in pathophysiological conditions, such as in blood ^[@R22],[@R27]^ and ascitic exudates ^[@R28]^. To definitively determine the specificity of Slc12a8 between NMN and NR, we gave doubly labeled, 3-Da heavier, isotopic NMN or NR (O18-D-NMN or O18-D-NR) to Slc12a8-OE and control NIH3T3 cells and measured these isotopic compounds transported into cells within 5 min. When treating with 25 μM O18-D-NMN, Slc12a8-OE cells showed approximately 4-fold higher uptake of O18-D-NMN compared to control cells but no increase in O18-D-NR, demonstrating unequivocal NMN uptake without any conversion of NMN to NR outside of cells within 5 min ([Fig. 2f](#F2){ref-type="fig"}). On the other hand, when treating with 25 μM O18-D-NR, equivalent levels of O18-D-NMN synthesis and equivalent transport of O18-D-NR were detected in both Slc12a8-OE and control cells ([Fig. 2f](#F2){ref-type="fig"}). These results clearly demonstrate that Slc12a8 specifically transports NMN, but not NR, in a minute-order.

We next assessed the ion dependency of Slc12a8 for NMN transport, using the Slc12a8-OE proteoliposome system. When sodium was replaced with lithium, the ^3^H-NMN incorporation was dramatically reduced by \~80% ([Fig. 2g](#F2){ref-type="fig"}), indicating that NMN transport by Slc12a8 is sodium ion-dependent. Potassium ion is not sufficient to elicit the NMN-transporting function of Slc12a8 ([Supplementary Fig. 2d](#SD1){ref-type="supplementary-material"}), and chloride ion is not required for NMN transport ([Fig. 2g](#F2){ref-type="fig"}), which distinguishes Slc12a8 from other known Slc12a family members that function as cation-chloride cotransporters ^[@R24],[@R29]^. Lastly, we compared the effect of Slc12a8 overexpression on NAD^+^ biosynthesis in NIH3T3 cells. When control and Slc12a8-OE NIH3T3 cells were pre-treated for 1 hr with a cocktail of 100 nM FK866, 2 μM dipyridamole, and 500 μM AOPCP, intracellular NAD^+^ levels were significantly reduced in both control and Slc12a8-OE cells ([Fig. 2h](#F2){ref-type="fig"}). However, additional 1-hr incubation with 100 μM NMN was able to restore NAD^+^ levels to the original levels only in Slc12a8-OE cells, not in control NIH3T3 cells ([Fig. 2h](#F2){ref-type="fig"}). Furthermore, this Slc12a8-mediated restoration of NAD^+^ was not affected by WNK463, a specific inhibitor for the WNK kinase that regulates the activity of the cation-chloride cotransporters ^[@R29]^ ([Supplementary Fig. 2e](#SD1){ref-type="supplementary-material"}). All these results strongly support the function and the specificity of Slc12a8 as a novel NMN transporter in mammals.

*In vivo* validation of the NMN transporter {#S5}
-------------------------------------------

To further evaluate the NMN-transporting function of Slc12a8 *in vivo*, we first knocked down *Slc12a8* in the small intestine, one of the tissues that have highest *Slc12a8* expression, by giving oral gavages of lentiviruses carrying control firefly luciferase (*fLuc*) shRNA or *Slc12a8* shRNA to young wild-type mice. Slc12a8 protein levels were reduced by \~60% in the jejunum and \~50% in the ileum in the mice receiving the *Slc12a8* shRNA-expressing lentivirus in the gut, compared to the mice receiving the *fLuc* shRNA-expressing lentivirus ([Fig. 3a](#F3){ref-type="fig"}). When orally administering NMN (500 mg/kg body weight) to those mice, plasma NMN levels significantly increased at 5 min in the control mice, whereas they did not increase at all in the *Slc12a8*-KD mice ([Fig. 3b](#F3){ref-type="fig"}). Instead, plasma nicotinamide levels tended to be higher in *Slc12a8*-KD mice compared to control mice ([Fig. 3c](#F3){ref-type="fig"}), probably because higher levels of NMN were subjected to degradation to nicotinamide in *Slc12a8*-KD mice. Consistent with these results, NAD^+^ levels were significantly decreased in the jejunum of *Slc12a8*-KD mice compared to control mice ([Fig. 3d](#F3){ref-type="fig"}). In the ileum, there were small NAD^+^ decreases, which did not reach statistical significance, in *Slc12a8*-KD mice ([Fig. 3d](#F3){ref-type="fig"}). These results suggest that Slc12a8 in the small intestine is important to transport NMN from the gut into the circulation, affecting NAD^+^ levels in the small intestine and the systemic NMN supply *in vivo*.

We also produced whole-body *Slc12a8* knockout (*Slc12a8*KO) mice by excising the exon 4 of the *Slc12a8* gene using the CRISPR-CAS9 system. The birth ratio of these knockout mice was lower than the expected Mendelian ratio, implying that there was some premature death during the embryonic stage. However, the pups that were born safely were able to grow to adults, and they did not show any gross abnormalities. In these adult *Slc12a8*KO mice, we confirmed that the expression of the full-length *Slc12a8* mRNA was completely abolished in tissues ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}). We also confirmed that the Slc12a8 protein was abolished in the jejunum, ileum, and pancreas of the *Slc12a8*KO mice by Western blotting ([Fig. 3e](#F3){ref-type="fig"} and [Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}). The duodenum does not express the Slc12a8 protein ([Fig. 3e](#F3){ref-type="fig"}), even though it expresses high levels of *Slc12a8* mRNA ([Fig. 1b](#F1){ref-type="fig"}). Immunostaining signals of Slc12a8 in the gut, which are detected predominantly in apical, lateral, and basal membranes of the villi in the jejunum and ileum of wild-type mice, were abolished in *Slc12a8*KO mice ([Fig. 3f](#F3){ref-type="fig"} and [Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}), confirming the localization of Slc12a8 in the gut epithelia. Consistent with these findings, the *Slc12a8*KO mice showed significant decreases in NAD^+^ levels in the jejunum and ileum, but not in the duodenum, particularly during the dark time when NAD^+^ levels usually rise ([Fig. 3g](#F3){ref-type="fig"} and [Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). NAD^+^ decreases were also detected in the pancreas during both light and dark times ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). To further confirm whether NMN transport is compromised in the small intestine of the *Slc12a8*KO mice, we conducted a gavage of doubly labeled, isotopic NMN (O18-D-NMN) and measured the direct uptake of O18-D-NMN into the jejunum and ileum. At 10 min after administering O18-D-NMN by oral gavage, we clearly detected O18-D-NMN in the wild-type jejunum and ileum, whereas the uptake of O18-D-NMN decreased by 46% and 36% in the jejunum and ileum of the *Slc12a8*KO mice, respectively ([Fig. 3h](#F3){ref-type="fig"}).

Lastly, by using primary hepatocytes from control and *Slc12a8*KO mice, we again compared the transport of O18-D-NMN and O18-D-NR. When treating with 100 μM O18-D-NMN, *Slc12a8*KO hepatocytes showed \~90% reduction in O18-D-NMN uptake, compared to control wild-type hepatocytes at 5 min ([Fig. 3i](#F3){ref-type="fig"}). Both cells showed no detectable levels of O18-D-NR ([Fig. 3i](#F3){ref-type="fig"}). On the other hand, when treating with 100 μM O18-D-NR, equivalent levels of O18-D-NMN synthesis were detected in both *Slc12a8*KO and control hepatocytes, although there appeared to be some compensatory increases in O18-D-NR uptake in *Slc12a8*KO hepatocytes ([Fig. 3i](#F3){ref-type="fig"}). These results provide strong support for the specificity and the minute-order kinetics of Slc12a8 as a novel NMN transporter.

*Slc12a8* maintains NAD^+^ levels in the aged gut {#S6}
-------------------------------------------------

It has been well documented that NAD^+^ decreases over age in multiple tissues ^[@R4]^. We found that the jejunum and ileum in 24 month-old mice also showed NAD^+^ decreases, compared to 2 month-old mice, although the difference did not reach statistical significance in the jejunum ([Fig. 4a](#F4){ref-type="fig"}). Consistent with this phenomenon, *Slc12a8* expression was also significantly upregulated in the aged ileum ([Fig. 4b](#F4){ref-type="fig"}). To investigate the biological relevance of this *Slc12a8* upregulation in the aged ileum, we first gave an oral gavage of NMN to young (3 month-old) and aged (26 month-old) wild-type mice. Although the absolute plasma NMN levels were lower throughout all time points in aged mice compared to young mice ([Fig. 4c](#F4){ref-type="fig"}), the fold increases of plasma NMN levels were higher in aged mice compared to young mice ([Fig. 4d](#F4){ref-type="fig"}). NAD^+^ levels were also increased in aged mice to the levels close to young mice after NMN oral gavage ([Fig. 4e](#F4){ref-type="fig"}), and their fold increases were equivalent between young and aged mice ([Fig. 4f](#F4){ref-type="fig"}), indicating that the upregulation of *Slc12a8* plays an important role in counteracting age-associated NAD^+^ decline in the small intestine. To further test this possibility, we conducted oral gavages of lentiviruses carrying control *fLuc* shRNA and *Slc12a8* shRNA to 2- and 24-month-old mice and examined their NAD^+^ levels in the gut. Knockdown efficiencies were similar between young and aged mice ([Supplementary Figs. 4a-b](#SD1){ref-type="supplementary-material"}). Significant NAD^+^ decreases were detected in the ilea of the aged, but not young, *Slc12a8*-KD mice ([Fig. 4g](#F4){ref-type="fig"}). Luminal NMN content in the jejunum and ileum did not show any significant differences between young and aged mice ([Supplementary Fig. 4c](#SD1){ref-type="supplementary-material"}). Contrarily, we also overexpressed *Slc12a8* in the small intestine of young wild-type mice by giving oral gavages of the *Slc12a8*-expressing lentivirus. The Slc12a8 protein was overexpressed \~1.5-fold in the ilea ([Supplementary Fig. 4d](#SD1){ref-type="supplementary-material"}), which induced significant NAD^+^ increases in the ileum ([Supplementary Fig. 4e](#SD1){ref-type="supplementary-material"}). Taken together, these results demonstrate that the upregulation of *Slc12a8* in the ileum contributes to the maintenance of NAD^+^ levels in the aged intestine.

Discussion {#S7}
==========

We have previously demonstrated that the transport of NMN from the gut to the circulation and then to tissues occurred within 10 min ^[@R15]^. However, the mechanism that mediates such minute-order transport of NMN has so far remained unknown. In this study, we demonstrate that the *Slc12a8* gene encodes a novel NMN transporter in mammals. The mRNA expression of the *Slc12a8* gene is upregulated in response to NAD^+^ decline, allowing cells to meet to an urgent demand of NAD^+^ biosynthesis. The Slc12a8 NMN transporter is specific to NMN and requires the sodium ion for the transport of NMN. The abrogation or the deficiency of *Slc12a8* in cell culture and in the small intestine significantly reduces the uptake of NMN, resulting in reduced NAD^+^ levels in the jejunum and ileum *in vivo*. Conversely, cellular and intestinal overexpression of full-length *Slc12a8* provides a full capacity of NMN transport to the cells that otherwise exhibit minimal NMN transport and also increases ileal NAD^+^ levels *in vivo*, respectively. Furthermore, the whole-body *Slc12a8*KO mice display significant defects in direct, minute-order NMN transport and NAD^+^ biosynthesis, particularly in the jejunum and ileum. In the aged ileum, *Slc12a8* expression is upregulated in response to decreased NAD^+^ content. Perturbation of this *Slc12a8* upregulation in the aged ileum affects homeostatic regulation of ileal NAD^+^, causing further decreased NAD^+^ in the aged ileum. Thus, this newly identified NMN transporter encoded by the *Slc12a8* gene, namely, the transmembrane nucleotide transporter identified for the first time in mammals, functions to regulate NMN-driven NAD^+^ biosynthesis and maintain intestinal NAD^+^ levels in aged individuals.

How NMN is transported into cells has long been a matter of debate in the field of NAD^+^ biology. It has been believed that NMN needs to be converted first to NR by CD73 outside of cells and then NR is transported into cells, likely through the nucleoside transporter, and reconverted to NMN by NRK1/2 ^[@R21],[@R30]^. Although this process can occur over the course of 24h ^[@R21]^, such hourly kinetics cannot explain the minute-order uptake of NMN into the cell. Additionally, how to analyze the *in vivo* kinetics of NMN is also critical, and the results could be significantly affected by differences in sample collection and extraction methodologies ^[@R22],[@R23]^. For example, plasma samples need to be processed immediately after collection, as we did in this study, because freezing blood or plasma samples causes inaccurate measures of NMN levels. The results presented in this study strongly indicate that Slc12a8 is specific to NMN, not to NR, and its *K*~*m*~ is consistent with a measured range of NMN concentrations ^[@R20],[@R25],[@R26]^. Even NaMN, structurally very close to NMN, cannot be transported by Slc12a8. Furthermore, its dependency on sodium ion, but not chloride or potassium ions, and its insensitivity to WNK463 distinguish Slc12a8 from other known cation-chloride cotransporters. Nonetheless, because a very high, supra-physiological concentration of NR can compete against NMN, NR might be able to interact with Slc12a8 weakly. To elucidate the precise details of the structure-function relationship between Slc12a8 and NMN, it will be of great importance to determine the crystal structure of the Slc12a8 NMN transporter.

The results from gut-specific *Slc12a8*-KD mice and whole-body *Slc12a8*KO mice demonstrate that the major place where NMN is absorbed is the small intestine, particularly the jejunum and ileum. Whereas we can detect NMN in the luminal content of the jejunum and ileum, the source of NMN remains unknown at this moment. For humans, certain vegetables and fruits contain NMN ^[@R15]^. Additionally, it has been reported that human and cow milk contains NMN at micromolar concentrations ^[@R31],[@R32]^. For mice, one interesting possibility is that NMN could be produced from the enzymatic degradation of NAD^+^ in the small intestine. Another possibility is that certain gut bacterial species may produce NMN. If this is the case, the Slc12a8 NMN transporter would likely play a critical role in the symbiotic regulation of NAD^+^ biosynthesis between the microbiota and the host.

Remarkably, the function of the Slc12a8 NMN transporter becomes crucial in aged individuals compared to young ones. In response to significant decreases in NAD^+^ levels, the aged ileum upregulates *Slc12a8* expression and tries to maintain its NAD^+^ levels. When enough NMN is supplied, this feedback system can function adequately to maintain comparable levels of NAD^+^ to those in young ilea. Therefore, increasing NMN availability or stimulating the function of the NMN transporter could effectively counteract age-associated NAD^+^ decline in the aged small intestine. In addition to aging, the NMN-transporting function of Slc12a8 might also be important for the pathogenesis of some diseases. For example, the human SLC12A8 gene has been identified as a psoriasis susceptibility candidate gene ^[@R33]^. Most recently, it has been reported that the high expression of SLC12A8 and its genetic polymorphism are associated with better prognosis of patients with pancreatic ductal adenocarcinomas ^[@R34]^ and breast cancers ^[@R35]^, respectively. Thus, the Slc12a8 NMN transporter could be a new, interesting target for pharmaceutical drug development.

In conclusion, the identification and the characterization of the Slc12a8 NMN transporter further advances our understanding of the physiological importance of NMN as a key systemic NAD^+^ intermediate. Because NMN conveys remarkable effects of mitigating age-associated physiological decline in mice ^[@R4],[@R15]^, identifying compounds that could promote the NMN-transporting function of the Slc12a8 protein will provide an interesting opportunity to develop a more effective anti-aging intervention, combined with NMN administration.

Methods {#S8}
=======

Microarray Analysis. {#S9}
--------------------

Total RNA was isolated from primary hepatocytes, pancreatic islets, and hippocampal neurospheres, treated with 0.1% DMSO (control) or FK866 (200 nM for primary hepatocytes, and 10 nM for pancreatic islets and hippocampal neurospheres). Primary hepatocytes and pancreatic islets were isolated from 3 month-old C57BL/6J (B6) male mice (Jackson Laboratories). To determine transcriptional changes induced by FK866 treatment, microarray analyses were conducted using the Illumina Mouse Ref 8 whole genome microarrays (version 2). The background-subtracted raw microarray data were subjected to Z score transformation, and Z ratios were calculated as described previously ^[@R5]^. All data were analyzed by the R statistical software package.

Cell culture and *ex vivo* small intestine explant culture. {#S10}
-----------------------------------------------------------

NIH3T3 cells (originally purchased from the American Type Culture Collection \[ATCC\]) were cultured at 37 °C and 5% CO~2~ in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin. For *Slc12a8* mRNA expression analysis, 2.5 × 10^5^ cells per well were incubated in 6-well plates with DMEM with 1% FBS containing 0.1% DMSO or 100 nM FK866 or 100 nM FK866 plus 100 μM NMN for 24h. Small intestines from 3 month-old C57BL/6J (B6) male mice (Jackson Laboratories) were cut into three segments with duodenum/jejunum/ileum length ratios of 1:3:2 ^[@R36]^. One centimeter of each segment was opened longitudinally, washed once with cold PBS, and incubated for 4h at 37°C with 0.1% DMSO or 100 nM FK866 or 100 nM FK866 plus 500 μM NMN in the 1:1 mixture of DMEM and Ham's F-12 medium (Sigma) with 5% FBS and the following additives: 5 μg/ml insulin (Sigma), 20 ng/ml epidermal growth factor (Sigma), 1x B27 supplement (GIBCO), 1 mM Sodium pyruvate (Corning), 100 units/ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamax (GIBCO). Cellular and tissue total RNA samples, which were extracted using the PureLink RNA Mini kit (Cat\# 12183025, Ambion), were analyzed by quantitative RT-PCR, and relative expression levels were calculated for each gene by normalizing to *Gapdh* expression levels ^[@R16]^.

NAD^+^ and NMN measurements by HPLC. {#S11}
------------------------------------

NAD^+^ and NMN were extracted from cells and tissues with perchloric acid, neutralized with K~2~CO~3~ on ice, and quantitated by our high-performance liquid chromatography (HPLC) system (Shimadzu) with a Supelco LC-18-T column (15cm × 4.6cm; Sigma) and a Hypercarb column (15cm × 4.6cm; Thermo Scientific), respectively ^[@R5],[@R37]^.

Flow cytometry analysis. {#S12}
------------------------

2 × 10^6^ NIH3T3 cells were incubated in a 10-cm culture dish with DMEM with 1% FBS containing 0.1% DMSO or 100 nM FK866 or 100 nM FK866 plus 100 μM NMN for 48h at 37°C and 5% CO~2~. Cells were then washed once with cold PBS, treated with 0.02% EDTA in PBS, and stained for flow cytometry using a commercially available polyclonal rabbit anti-mouse Slc12a8 antibody (ARP44039, Aviva, CA) at 1:200, a secondary goat anti-rabbit IgG (H+L) conjugated with Alexa Fluor 488 at 1:2000 (Invitrogen), and the survival marker Zombie Dye at 1:400 (Biolegend) for 25 min at 4˚C. Cells were then washed and analyzed by the Gallios Flow Cytometer (BeckmanCoulter). For the intracellular staining, cells were first fixed in 2% PFA for 10 min at room temperature and then permeabilized in saponin-containing buffer for another 10 min at RT. Slc12a8 staining was performed in permeabilization buffer for 25 min at 4°C. Samples were analyzed by the Gallios Flow Cytometer, and data were analyzed using Kaluza 1.3 (BeckmanCoulter). Dead cells were excluded using a Zombie Aqua Fixable Viability Kit (Biolegend).

Hepatocytes isolation, 5'-nucleotidase activity assay, NMN uptake measurement, and silencing of *Slc12a8* and *Nrk1* expression. {#S13}
--------------------------------------------------------------------------------------------------------------------------------

Primary hepatocytes were isolated from 3 month-old B6 male mice (Jackson Laboratories) by a two-step hepatic portal perfusion with calcium and magnesium-free Hanks' salt solution followed by DMEM containing 0.25 mg/mL collagenase (Type IV, Cat \# C5138, Sigma) ^[@R38]^. Cells were cultured overnight in 6-well plates coated with poly-L-lysine at 37°C and 5% CO~2~ in DMEM supplemented with 10% FBS, 100 units/ml penicillin, and 100 μg/ml streptomycin (pen/strep) before conducting any experiments. *Slc12a8* mRNA expression and NAD^+^ content were evaluated by incubating hepatocytes with 500 nM FK866 or 500 nM FK866 plus 500 μM NMN in DMEM with 1% FBS for 24h. To make sure whether adenosine-5′-\[α, β-methylene\]diphosphate (AOPCP) inhibits 5'-nucleotidase activity, 1.5 × 10^5^ cells per well were grown in 12-well plates with 500 nM FK866 in DMEM with 1% FBS for 24h and then incubated in 1.4 ml of Hanks' buffered saline solution with Ca^2+^ and Mg^2+^ at pH 7.5 (HBSS, GIBCO) in the presence of 100 μM adenosine monophosphate (AMP) or 100 μM AMP plus 500 μM AOPCP. At different time points (0, 1, 5, 15, and 30 min), 200 μl of each culture supernatant were collected and extracted by adding 28 μl of 70% perchloric acid. The amounts of adenosine produced were determined by HPLC. Elution times for AMP and adenosine were 4.7 and 17.4 min, respectively. To examine cell viability, Celltiter 96 AQueous One Solution Cell Proliferation Solution (Promega, MA) was used, and the absorbance was measured at λ=490 after 4h incubation. For NMN uptake measurement, 1.5 × 10^5^ cells per well were grown in 12-well plates with 500 nM FK866 in DMEM with 1% FBS for 24h and then incubated in 1 ml of HBSS in the presence of 500 μM AOPCP, 20 μM dipyridamole, and 500 nM FK866 or these inhibitors plus 100 μM NMN. At different time points (0, 0.25, 1, 5, 15, and 30 min), cells were washed once with cold HBSS and lysed in cold 10% perchloric acid. Intracellular NMN levels were measured by HPLC as described previously ^[@R5]^. For gene silencing experiments, 10 μg of ON-TARGET plus mouse siRNA (Thermo scientific) specific to *Slc12a8* (J-042450--12-0020) or *Nrk1* (J 051839--11-0010) or a negative control siRNA (NON-targeting siRNA \#1, D-001810--01-20) were electroporated into one million cells per condition, mixed with 100 μl AMAXA Mouse Hepatocyte Nucleofector Solution (Lonza), using the Nucleofector program H-26 following the manufacturer's instructions. The electroporated cells were incubated in the cuvette for 15 min before addition of media. 2.5×10^5^ cells per well were seeded in 6-well plates coated with poly-L-lysine at 37°C and 5% CO~2~ in DMEM containing 10% FBS and penicillin-streptomycin for 48h after electroporation. Those cells were incubated with 500 nM FK866 in DMEM with 1% FBS for 24h. NMN uptake was measured by HPLC after incubating cells in HBSS with 500 μM AOPCP, 20 μM dipyridamole, and 500 nM FK866 or these inhibitors plus 100 μM NMN for 1 min at room temperature. Silencing efficiencies were evaluated by quantitative RT-PCR.

Generation of NIH3T3 cells stably overexpressing the full-length mouse *Slc12a8* cDNA. {#S14}
--------------------------------------------------------------------------------------

The coding region of full-length mouse *Slc12a8* cDNA (GenBank Reference Sequence: NM_134251) was amplified from mouse liver by PCR using PfuUltra II Fusion HS DNA polymerase (Agilent, CA) with the following forward and reverse primers containing XhoI sites:*Slc12a8* forward: 5'-ATACTCGAGGAGAATGGCCCAGAGGTCTC-3', *Slc12a8* reverse: 5'- TCAACTACGGAGGGATGATCGAGCTCATT −3'

The resulting 2118-bp fragment of full-length *Slc12a8* cDNA was digested with XhoI and cloned into pBluescript SK- vector. *Slc12a8* cDNA fragment was then subcloned into the mammalian expression vector pCXN2 ^[@R39]^. N- or C-terminally FLAG-tagged versions of full-length *Slc12a8* cDNA were produced using the following forward and reverse primer sets containing XhoI sites and FLAG-tag sequences:, N-terminally FLAG-tagged *Slc12a8,* Forward: 5'-ATACTCGAGCCACCATGGACTACAAAGACGATGACGACAAGGGCGCCCAGAGGTCTCCG-3'Reverse: 5'- TCAACTACGGAGGGATGATCGAGCTCATT −3'C-terminally FLAG-tagged *Slc12a8*Forward: 5'- ATACTCGAGCCACCATGGCCCAGAGGTCTCCG −3'Reverse: 5'-TCAACTACGGAGGGATGCCGCTGATGTTTCTGCTACTGCTGTTCATCGAGCTCATT −3'

The resultant FLAG-tagged *Slc12a8* cDNA fragments were cloned into the mammalian expression vector pIRES-EGFP-puro (Addgene, Cat\#45567). The *Slc12a8* cDNA sequence in the final vector was confirmed by sequencing. NIH3T3 cells were transfected with 5 μg of pCXN2 carrying the full-length *Slc12a8* cDNA (Slc12a8-OE) or only pCXN2 vector (control) or 5 μg of pIRES-EGFP-puro carrying the full-length Slc12a8 cDNA with N- or C-terminal FLAG-tag (Slc12a8-OE) or only pIRES-EGFP-puro vector (control) using the SuperFect transfection reagent (QIAGEN) and cultured in DMEM supplemented with 10% FBS, antibiotics, and 300 μg/ml G418 (Invitrogen) or 1 μg/ml puromycin (Sigma, MO) for 2 weeks. Resistant cells were pooled, and aliquots were frozen for further experiments. To confirm Slc12a8 protein expression levels, plasma membrane (PM) fractions were prepared from control and Slc12a8-OE cells or N- or C-terminally FLAG-tagged Slc12a8-OE cells, as described previously ^[@R40]^. Briefly, 7.5×10^7^ cells cultured in five 10-cm dishes were used. After 2 washes with ice-cold HES buffer (20 mM HEPES, 1 mM EDTA, and 255 mM sucrose, pH 7.4), cells were collected by scraping in HES buffer (3 ml/dish) containing a protease inhibitor cocktail (Roche) and homogenized by passing 5 times through a 22-gauge needle. All subsequent steps were performed at 4°C. The homogenate was centrifuged (Avanti J-E; Beckman-Coulter) at 10,000 g in a JA 25.5 rotor for 15 min. The resulting supernatant was layered on the top of a 10-ml sucrose cushion (38.5% sucrose, 20 mM HEPES, and 1 mM EDTA, pH 7) and centrifuged at 53,000 g for 120 min. The interface containing the PM fraction was carefully removed, resuspended in 10 ml HES buffer, and centrifuged at 50,000 g for 30 min, yielding the PM fraction in the pellet. PM fractions from control or Slc12a8-OE cells were lysed with RIPA buffer (150 mM sodium chloride, 1.0% NP-40, 0.25% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5, 2 mM EDTA, 1 mM PMSF, 0.5mM DTT and protease inhibitor cocktail) and boiled for 5 minutes in 1x Laemmli buffer. Western blotting was conducted with rabbit polyclonal anti-mouse Slc12a8 (1:500, ARP44039, Aviva, CA) or monoclonal anti-FLAG MS (1:500, \#F3165, Sigma, MO), and anti-Caveolin-1 (1:2000, \#3238, Cell Signaling, MA) antibodies. Band intensity was quantitated on the Amersham Hyperfilm™ ECL (GE Healthcare limited) by Photoshop. To measure intracellular NAD^+^ levels, 2×10^5^ control and Slc12a8-OE NIH3T3 cells were preincubating with 2 μM dipyridamole, 500 μM AOPCP, 100 nM FK866, and in some experiments, 10 μM WNK463, a pan-WNK kinase inhibitor (MCE, \# HY-100626), for 1h and then with the same inhibitors combined with 100 μM NMN for an additional 1h in DMEM 1%FBS at 37°C. At the end of incubation, cells were washed once with cold PBS and lysed in 10% perchloric acid. NAD^+^ levels were determined by HPLC, as described above.

NMN uptake analyses with radiolabeled NMN. {#S15}
------------------------------------------

Control and Slc12a8-OE NIH3T3 cells were harvested by centrifugation (400g, 5 min), washed once in HBSS, and incubated at 37°C in HBSS \[pH 7.5\] (5×10^6^ cells/ml) containing 100 nM ^3^H-β-nicotinamide mononucleotide (9 Ci/mmol; Moravek Biochemicals, CA) and unlabeled NMN to make the final concentration 25 μM. At the designated time points (1, 3, 5 and 10 minutes), aliquots of the cells (100 μl) were collected and placed in 1.5-ml microcentrifuge tubes containing silicone-mineral oil (density, 1.015; Sigma-Aldrich) on the top of 2 M potassium hydroxide solution, followed by centrifugation at 16,000g for 30s. Cells were separated from the buffer and pelleted through the silicone-mineral oil layer. The radioactivity in these cell pellets was determined by a liquid scintillation counter. For calculating *K*~*m*~ and *V*~*max*~, we used the same condition described above, but with various total concentrations of NMN, ranging from 1 μM to 100 μM. At the 4-min time point, 100 μl of cell suspension was collected and pelleted in the same way described above. The radioactivity in cell pellets was determined by a liquid scintillation counter. The radioactivity measured in control NIH3T3 cells was subtracted to calculate Slc12a8-specific NMN uptake in Slc12a8-OE NIH3T3 cells.

Proteoliposome experiments. {#S16}
---------------------------

Proteoliposome preparation was carried out as previously described ^[@R41]^. Briefly, 2×10^7^ control or Slc12a8-OE NIH3T3 cells were resuspended in 1 ml of lysis buffer (10 mM Tris-HCl, pH 8.3, 150 mM NaCl, 0.3 M sucrose, protease inhibitor cocktail) and disrupted using a homogenizer. The lysate was centrifuged for 10 min at 3,000g, and the supernatant was collected and centrifuged for 15 min at 100,000g. The membrane proteins were solubilized with buffer A (10 mM Tris-HCl \[pH 8.3\] containing 150 mM NaCl and 0.5% n-octyl-β-glucopyranoside). Separately, total lipids were extracted from hemoglobin-free erythrocyte membranes (ghosts) as described previously ^[@R42]^. Total lipids from human erythrocyte membranes (3 mg) were dried and resuspended with 600 μl of solubilized membrane proteins (at approximately 0.7 mg/ml protein concentration). The resulting emulsions were sonicated in ice for 1 min and dialyzed against 5 liters of buffer A without n-octyl-β-glucopyranoside (dialysis buffer) for 24h at 4°C. Proteoliposomes were recovered, centrifuged for 15 min at 100,000g, resuspended in 900 μl dialysis buffer and passed 5 times through a 30-gauge needle. To examine the Na^+^-, K^+^- or Cl^-^-dependency of Slc12a8, NaCl was replaced with 150 mM LiCl, KCl, or CH~3~COONa, respectively. All steps were carried out at 4°C. Proteoliposomes (30 μl in triplicate for each condition) were incubated for 2, 5, and 10 min at 25°C in the presence of 150 nM (10^5^ cpm/ml) ^3^H-β-NMN (specific activity, 9.1 Ci/mmole) with or without 150 μM label-free compounds (NMN, NR, NAD, AMP, nicotinic acid mononucleotide \[NaMN\], and nicotinamide). At the end of incubations, samples were filtered on a glass fiber paper. Filters were washed with 3 ml of dialysis buffer, dried, and counted for radioactivity. In each experiment, we always measured the non-specific binding/uptake of ^3^H-NMN by adding 150 nM ^3^H-NMN and 300 μM of cold NMN (2000-fold higher concentration) to the proteoliposomes derived from Slc12a8-OE NIH3T3 cells and measuring the radioactivity of ^3^H-NMN after extensive washes. Because specific NMN transport should be displaced completely by the 2000-fold higher concentration of cold NMN, ^3^H-NMN detected in this condition must be due to a non-specific/non-kinetic transport and/or a non-specific binding to proteoliposomes. Such values due to non-specific transport/biding of ^3^H-NMN were always measured in each experiment and subtracted from all measured values of ^3^H-NMN transported into proteoliposomes in each condition. To examine whether Slc12a8 could transport NaMN, proteoliposomes (300 μl in triplicate for each condition) were incubated for 5 min with 5 mM NMN or NaMN (Sigma, \#N7764). Right after incubation, samples were filtered on a glass fiber paper (0.25 cm^2^ area), and nucleotides were extracted with 200 μl of 0.6 M perchloric acid. Extracts were neutralized with 2 M K~2~CO~3~, and nucleotides were quantitated by HPLC.

*In vivo Slc12a8* knockdown and overexpression. {#S17}
-----------------------------------------------

To generate shRNA-expressing lentiviral constructs, 56-bp double-stranded oligonucleotides, each of which contains a sense target sequence, a microRNA-based loop sequence (CTTCCTGTCA), an antisense sequence, a termination sequence of four thymidines, and appropriate restriction enzyme sites at both ends, were generated for mouse *Slc12a8* and firefly luciferase (*fLuc*) and cloned into the U6-PGK-GFP vector provided by the Viral Vectors Core at Washington University School of Medicine. The sense *Slc12a8* sequence is '5--5GCCTAGAGTGAACAGAGAAGA-3'. To generate the *Slc12a8*-expressing lentiviral construct, a 2118-bp fragment of full-length *Slc12a8* cDNA was subcloned into the FCIV.FM1 vector provided by the Viral Vectors Core. Lentiviruses were produced by co-transfecting HEK293T cells with the shRNA- or *Slc12a8*-expressing vectors and three packaging vectors (pMD-Lg, pCMV-G, and RSV-REV) using SuperFect transfection reagent (QIAGEN). Culture supernatant was collected 48 hr after transfection ^[@R43]^. Knockdown or overexpression efficiencies were tested using primary intestinal cultures ^[@R44]^. Large-scale lentivirus production was carried out by the Viral Vectors Core at the Hope Center for Neurological Disorders at Washington University. C57BL/6J mice (Jackson Laboratories) orally received *fLuc* or *Slc12a8* shRNA lentivirus with a titer of 5 × 10^6^ transduction units or vector-only or Slc12a8-expressing lentivirus with a titer of 3 × 10^6^ transduction units after an overnight fast for two consecutive days.

Generation of antibodies against mouse Slc12a8 and tissue Western blot analysis. {#S18}
--------------------------------------------------------------------------------

Two different polyclonal rabbit antisera were produced against a synthetized N-terminal peptide (AQRSPQELFHEAAQQGC) of mouse Slc12a8 (Covance, PA). Mouse tissues were homogenized with RIPA buffer and boiled in 1x Laemmli buffer for 5 min. Western blotting was conducted with a rabbit polyclonal antiserum against the N-terminal portion of mouse Slc12a8 (1:500, Covance, PA) and an anti-Gapdh antibody (1:1000, MAB374, Millipore, MO). Band intensity was quantitated on the Amersham Hyperfilm^tm^ ECL (GE Healthcare limited) by Photoshop.

Generation of the whole-body *Slc12a8* knockout mice. {#S19}
-----------------------------------------------------

Whole-body *Slc12a8* knockout (*Slc12a8*KO) mice were generated with the CRISPR-CAS9 technology by the Transgenic Vectors Core of Washington University. CRISPR gRNAs were designed to flank exon 4 of the *Slc12a8* gene. gRNA sequences were as follows: 5' gRNA; 5'- agtgcatgtatagacgtatg - 3' and 3' gRNA; 5' - cctcacaaatatttacaggc - 3'. gRNAs were obtained as gBlocks (IDT). Cleavage activity was assessed by transfecting N2A cells with gBlock and Cas9 plasmid (addgene \# 42230) using XtremegeneHP (Roche). Cleavage activity was determined by T7E1 assay using standard methods. gRNA was *in vitro* transcribed using the T7 Megashort Script Kit (Ambion). Cas9 RNA was *in vitro* transcribed using the mMessage mMachine T7 Ultra Kit (Ambion). All RNA was purified using Megaclear Columns (Ambion). RNA was microinjected into C57BL/6J × CBA hybrid zygotes at a concentration of 50 ng/μl Cas9, 25 ng/μl gRNA, and 100 ng/μl ssODN in the Washington University Mouse Genetic Core Facility. Whole-body knockout alleles were detected by PCR across the cleavage site and confirmed by sequencing. One heterozygous founder was established, and the mice were backcrossed to wild-type C57BL/6J mice (Jackson Laboratories) for 5 generations before analysis. *Slc12a8*-deficient heterozygous mice were crossed to generate homozygous Slc12a8KO mice. Wild-type littermates were used as controls.

Production of O18-D-NR and O18-D-NMN. {#S20}
-------------------------------------

^18^O nicotinamide was prepared from the hydrolysis of cyanopyridine in ^18^O water ^[@R45]^. 1,2-^2^H,3,5-tetraacetate was synthesized from D-\[2-^2^H\]-ribose (purchased from Omicron Biochemicals) ^[@R46]^. ^18^O-^2^H labelled nicotinamide riboside (O18-D-NR) was synthesized from ^18^O-nicotinamide and D-ribofuranose 1,2-^2^H,3,5-tetraacetate ^[@R47]^. ^18^O-^2^H nicotinamide mononucleotide (O18-D-NMN) was synthesized from ^18^O-^2^H nicotinamide riboside, as described previously ^[@R15]^.

Isotopic tracing experiment. {#S21}
----------------------------

3×10^5^ primary hepatocytes isolated from 5 month-old male *Slc12a8*KO mice and their wild-type littermates were incubated in 6-well plates with 100 μM O18-D-NMN or O18-D-NR in DMEM with 1% FBS for 5 min at 37°C. 3×10^5^ control and Slc12a8-OE NIH3T3 cells were incubated in 6-well plates with 25 μM O18-D-NMN or O18-D-NR in DMEM with 1% FBS for 5 min at 37°C. After incubation, cells were washed twice with cold PBS and lysed in a cold 1:1 mixture of reagent-grade methanol and water. Seven-to-eight month-old *Slc12a8*KO mice and their wild-type littermates were orally administered with O18-D-NMN at a dose of 500mg/kg or PBS after an overnight fast. The jejunum and ileum were collected at 10 min after oral gavage. A 1:1 mixture of reagent-grade methanol and water (4°C) were added to the frozen tissue (60 μL/mg tissue). After sonication, extracts were centrifuged at 12,000g for 15 min at 4°C. Chloroform was added to the extracts at a ratio of 1:1 (v/v), thoroughly shaken for 30s, and centrifuged at 12,000g for 10 min at 4°C. The upper phase (methanol and water) was separated from the lower (organic) phase and lyophilized by speed vacuum at room temperature, reconstituted with 5 mM ammonium formate and centrifuged at 12,000g for 10 min. Serial dilutions of NMN, O18-D-NMN, and O18-D-NR at concentrations ranging 128--1000 nmol/L in 5 mM ammonium formate were used for calibration. Liquid chromatography was performed by HPLC (1290; Agilent) with Atlantis T3 (LC 2.1 × 150mm, 3 mm; Waters) at a flow rate of 0.15 ml/min with 5 mM ammonium formate for mobile phase A and 100% methanol for mobile phase B. Metabolites were eluted with gradients of 0--10 min, 0--70% B; 10--15 min, 70% B; 16--20 min, 0% B. The metabolites were analyzed with a Triple Quadrupole mass spectrometer (6470; Agilent) under positive ESI multiple reaction monitoring (MRM) using parameters for NMN (335\>123), O18-D-NMN (338\>125), and O18-D-NR (258\>125). Fragmentation, collision, and post acceleration voltages were 135V, 8V, 7V for NMN and 130V, 20V, 1V for NR. Peaks of NMN, O18-D-NMN, and O18-D-NR were identified using the MassHunter quantitative analysis tool (Agilent). The areas under the peaks of O18-D-NMN and O18-D-NR were calculated by subtracting the background values of PBS controls.

Animal experimentation. {#S22}
-----------------------

All mice were group-housed in a barrier facility with 12hr light/12hr dark cycles. Mice were maintained *ad libitum* on a standard chow diet (LabDiet 5053; LabDiet, St. Louis, MO). For plasma NMN kinetics and tissue NAD^+^ detection, 3--4 month-old male C57BL/6J mice (Jackson Laboratories) that received an oral gavage of *fLuc* or *Slc12a8* shRNA lentivirus, and 3 and 26 month-old female C57BL/6J mice (Charles River) were fasted overnight. Blood was collected from their tail veins at 0, 5 and 60 min after an oral gavage of NMN (500 mg/kg) or PBS. Immediately after blood collection, plasma was separated and quickly extracted with perchloric acid. At this step, it is critical to avoid freezing plasma samples. To show the importance of this procedural precaution, we gave an oral gavage of doubly labeled isotopic NMN (O18-D-NMN) to seventh-month old male C57BL/6J mice (Jackson Laboratories) and measured O18-D-NMN (M+3), O18-NMN (M+2), and NMN (M+0) at 5 min by extracting plasma samples freshly (without freezing/thawing). In this experimental condition, we were able to detect O18-D-NMN (M+3) reliably in plasma samples at 5 min after oral gavage ([Supplementary Fig. 4f](#SD1){ref-type="supplementary-material"}), different from the recently reported results ^[@R23]^. Indeed, extraction of NR from human plasma samples also require a similar caution ^[@R22]^. Tissue samples were also collected at 60 min time points after an oral gavage of NMN (500 mg/kg) or PBS. NAD^+^ levels and *Slc12a8* mRNA expression were determined in tissues from 2- or 24-month-old female C57BL/6J mice (Jackson Laboratories) or those in which *Slc12a8* was knocked down specifically in the small intestine, as described above. Luminal NMN content was compared by mass spectrometry in the jejunum and ileum between 3 and 26 month-old female C57BL/6J mice (Charles River) fasted overnight. All animal studies were approved by the Washington University Institutional Animal Care and Use Committee and were in accordance with NIH guidelines.

Immunostaining of Slc12a8 in the small intestine. {#S23}
-------------------------------------------------

Jejuna and Ilea were prepared by the Swiss-roll method and fixed overnight in 10% buffered formalin (Sigma-Aldrich). Fixed tissues were dehydrated, embedded in paraffin, and sectioned at 5-μm thickness by the Elvie L. Taylor Histology Core Facility of Washington university. Antigen retrieval was performed in sodium citrate buffer (10 mM Tris-sodium citrate dihydrate \[pH 6.0\], 0.05% Tween 20) followed by blocking of endogenous peroxidase activity in 3% hydrogen peroxide in TBS-T (0.1M Tris-HCl \[pH 7.5\], 0.15M NaCl, 0.05% Tween 20). After blocking with 10% normal goat serum in TBS-T, samples were incubated overnight at 4ºC with a rabbit anti-mouse-Slc12a8 antibody (1:100, ARP44039, Aviva, CA) and subsequently with HRP-conjugated goat anti-rabbit IgG (1:1,000) antibody using the FITC TSA kit (Parkin Elmer) according to the manufacturer's protocol. Nuclei were stained with DAPI (Sigma \#D9542). Digital images were collected with a fluorescence microscope (ApoTome 2, Zeiss).

Statistical Analyses. {#S24}
---------------------

Differences between two groups were assessed using the unpaired, two-tailed Student's *t* test. Comparisons among several groups were performed using one-way ANOVA with various post hoc tests indicated in figure legends. Z ratios and two-sided *p* values for *Slc12a8* in [Figure 1a](#F1){ref-type="fig"} were calculated as previously described ^[@R48]^. For comparisons, *p* values \<0.05 were considered statistically significant. All experiments were performed independently at least twice. GraphPad Prism (Version 7) was used to conduct statistical analyses.
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![Identification and characterization of the *Slc12a8* gene. **a,** Venn diagram of genes commonly upregulated in primary hepatocytes, pancreatic islets, and hippocampal neurospheres treated with FK866. *Slc12a8* was identified in the section indicated by an arrow. Z ratios and two-sided *p* values for *Slc12a8* in each cell type were calculated as described in the Methods section (n=4 biologically independent samples). **b,** Relative *Slc12a8* mRNA levels in different tissues from B6 male mice at 3 months of age (n=4 mice). WAT, white adipose tissue. **c,** Relative *Slc12a8* mRNA levels in primary mouse hepatocytes (n=4 mice, \*\* p=0.0191, \*\*\*p=0.0006), NIH3T3 fibroblasts (n=4 biologically independent samples, DMSO vs. FK866 \*\*\*p=0.0004, FK866 vs. FK866 plus NMN \*\*\*p=0.0003), and *ex vivo* explants of the jejunum and ileum (n=4 mice for DMSO and FK866 alone; n=3 mice for FK866 plus NMN; Jejunum, DMSO vs. FK866 \*p=0.0168, FK866 vs. FK866+NMN \*p=0.0111; Ileum, DMSO vs. FK866 \*\*p=0.009, FK866 vs. FK866+NMN \*p=0.0313) treated with 0.1% DMSO, FK866 alone or FK866 plus NMN (24h for cells, and 4 h for explants; analyzed using ANOVA with Tukey's test). **d,** Time course of NMN uptake in mouse primary hepatocytes. Hepatocytes were pretreated with 500 nM FK866 for 24 h and then incubated with a cocktail of 20 μM dipyridamole, 500 μM AOPCP, and 500 nM FK866, with or without 100 μM NMN. NMN was measured by HPLC (n=4 mice, except for 3 data sets for 15 and 30 time points for inhibitors only; analyzed using ANOVA with Sidak's test, \*p=0.0262). **e,** Knockdown efficiencies of *Slc12a8* and *Nrk1* mRNA in mouse primary hepatocytes (n=5 mice for *Slc12a8* silencing and n=3 for *Nrk1* silencing; analyzed by unpaired two-sided *t*-test, si*Slc12a8* \*\*\*\*p\<0.0001, si*Nrk1* \*\*\*\*p\<0.0001). **f,** Increases in intracellular NMN content measured by HPLC in primary hepatocytes treated with scrambled, *Slc12a8*, and *Nrk1* siRNA at 1 min after addition of 100 μM NMN. Culture conditions were the same as described in **d** (n=5 mice for *Slc12a8* silencing and n=3 for *Nrk1* silencing; analyzed by ANOVA with Tukey's test, \*\*p=0.0052, \*p=0.0413). All values are presented as mean ± SEM.](nihms-1511128-f0001){#F1}

![The kinetic features of the Slc12a8 NMN transporter and its specificity, sodium dependency, and effects on NAD^+^ biosynthesis. **a,** Slc12a8 protein expression in plasma membrane fractions from control and Slc12a8-OE NIH3T3 cells (left panel). Slc12a8 protein levels normalized to caveolin-1 protein levels are shown for each cell line (right panel; n=4 independent experiments; analyzed by unpaired two-sided *t*-test, \*p=0.0271). **b,** Uptake of ^3^H-labeled NMN (^3^H-NMN; 25 μM, 37°C) in control and Slc12a8-OE NIH3T3 cells (n=12 biologically independent samples; analyzed by ANOVA with Sidak's test, \*p=0.0136, \*\*\*p=0.0001). **c,** *K*~*m*~ and *V*~*max*~ of Slc12a8 for NMN transport. Those values were determined by non-linear regression analysis by subtracting the backgrounds of control cells (n=5 biologically independent samples for 1 and 10 μM, and n=4 biologically independent samples for 25 and 100 μM). **d,** Substrate specificity of Slc12a8. Transport of ^3^H-NMN (150 nM, 25°C) into proteoliposomes derived from Slc12a8-OE cells was measured at 2 min in the presence of competing cold compounds (n=3 biologically independent samples, analyzed by ANOVA with Dunnett's test, \*\*\*\*p=0.0001; ns, not significant). **e,** The half maximal inhibitory concentrations (IC~50~) of NMN and NR. Data are shown as percentages of ^3^H-NMN uptake (n=3 biologically independent samples; IC~50~ was calculated by non-linear regression analysis). **f,** Intracellular levels of doubly labeled, isotopic NMN (O18-D-NMN) and NR (O18-D-NR) were measured by mass spectrometry in control and Slc12a8-OE NIH3T3 cells incubated with 25 μM O18-D-NMN or O18-D-NR for 5 min (n=6 biologically independent samples; analyzed by unpaired two-sided *t*-test, \*\*\*\*p\<0.0001). Values are expressed relative to O18-D-NMN or O18-D-NR levels detected in control NIH3T3 cells. **g,** Ion dependency of NMN uptake by Slc12a8. Sodium ion (Na^+^) or chloride ion (Cl^-^) was replaced with an equimolar concentration of lithium (Li^+^) or acetate, respectively (n=3 biologically independent samples, analyzed by unpaired two-sided *t*-test, \*\*p=0.0017). **h,** Intracellular NAD^+^ content was measured as described in the Methods section (n=9 biologically independent samples; analyzed by ANOVA with Tukey's test; control, DMSO vs inhibitors \*\*\*\*p\<0.0001; Slc12a8-OE, DMSO vs. inhibitors \*\*\*\*p\<0.0001, inhibitors vs. inhibitors+NMN \*\*\*\*p\<0.0001; control, inhibitors+NMN vs. Slc12a8-OE, inhibitors+NMN \*\*\*p=0.0002). All values are presented as mean ± SEM.](nihms-1511128-f0002){#F2}

![The *in vivo* knockdown (KD) of *Slc12a8* in the small intestine. **a,** Slc12a8 protein levels in control and *Slc12a8* KD jejunum and ileum samples. A representative Western blot is shown (left panel), and bar graphs show Slc12a8 protein levels normalized to Gapdh protein levels (right panel) (n=3 mice, repeated twice; B6 males at 3--4 months of age; analyzed by unpaired two-sided *t*-test, \*p=0.0324, \*\*p=0.0085). **b,** Plasma NMN levels after an oral gavage of NMN (500 mg/kg body weight) in control and *Slc12a8* KD mice (n=6 mice; B6 males at 3--4 months of age; analyzed by ANOVA with Sidak's test, \*\*p=0.0080). **c,** Plasma nicotinamide levels in the same mice described in **b** (n=6 mice). **d,** Tissue NAD^+^ levels in the jejunum and ileum samples collected at 60 min time point after an oral gavage, as described in **b** (n=5 mice for PBS, and n=8 for NMN; B6 males at 3--4 months of age; analyzed by ANOVA with Tukey's test; Jejunum, *shfLuc* PBS vs. NMN \*\*\*\* p\<0.0001, *shSlc12a8* PBS vs. NMN \*\*p=0.0029, *shfLuc* NMN vs. *shSlc12a8* NMN \*p=0.0029; Ileum, *shfLuc* PBS vs. NMN \*\*\*p=0.0003, *shSlc12a8* PBS vs. NMN \*\*p=0.0030 ). **e,** Slc12a8 and Gapdh proteins in tissue lysates of the duodenum, jejunum, and ileum of *Slc12a8*KO mice and wild-type littermates (WT) (n=3 mice). **f,** Immunostaining of Slc12a8 (green) in the jejunum from 10 month-old *Slc12a8*KO female mice and WT littermates (n=3 mice). Red, blue, and yellow arrowheads indicate apical, lateral and basal membranes, respectively. Scale bars: 50 μm. **g,** Tissue NAD^+^ levels in the jejunum and ileum from *Slc12a8*KO mice and WT littermates, collected during light time (9--10 am) or during dark time (9--10 pm) (n=5 mice for the light time, and n=4 mice for the dark time, except for the 3 data points for the jejunum of Slc12a8KO mice; females at 8--10 months of age; analyzed by unpaired two-sided *t*-test; Jejunum, dark time WT vs. *Slc12a8*KO \*\*p=0.0015, light time WT vs. dark time WT \*\*p=0.0093; Ileum, dark time WT vs. *Slc12a8*KO \*\*p=0.0069). **h,** Levels of doubly labeled, isotopic NMN (O18-D-NMN) in the jejunum and ileum by mass spectrometry at 10 min after orally administering 500 mg/kg of O18-D-NMN in *Slc12a8*KO mice and WT littermates (n=6 mice, 3 males and 3 females at 7--8 months of age, except for 2 males and 2 females for the wild-type ileum; analyzed by unpaired two-sided *t*-test, \*p=0.0239). Values are expressed relative to O18-D-NMN levels detected in WT. **i,** Intracellular levels of O18-D-NMN and O18-D-NR by mass spectrometry in primary hepatocytes isolated from 5 month-old *Slc12a8*KO male mice and WT littermates and incubated with 100 μM O18-D-NMN or O18-D-NR for 5 min (n=3 mice; analyzed by unpaired two-sided *t*-test, \*\*\*\*p\<0.0001). Values are expressed relative to O18-D-NMN or O18-D-NR levels detected in WT. All values are presented as mean ± SEM.](nihms-1511128-f0003){#F3}

![The age-associated upregulation of *Slc12a8* in the ileum and its effect on NMN uptake and ileal NAD^+^ biosynthesis in aged mice. **a, b,** NAD^+^ levels (**a**) and relative *Slc12a8* mRNA levels (**b**) in the jejuna and ilea from 2 month-old (2 mo) and 24-month-old (24 mo) B6 female mice. Tissue samples were collected during the dark time (9--10 pm) (n=4 mice for each age, analyzed by unpaired two-sided *t*-test; NAD^+^ levels, \*p=0.0492; *Slc12a8* mRNA levels, \*p=0.0269). **c, d,** Plasma NMN levels (**c**) and their relative changes (**d**) after an oral gavage of NMN (500 mg/kg body weight) in 3 month-old (3 mo) and 26 month-old (26 mo) B6 female mice (n=4 mice; analyzed by ANOVA with Sidak's test; **c,** \*p= 0.0328, \*\*\*p=0.0010; **d,** \*p= 0.0257). **e, f,** Ileal NAD^+^ levels (**e**) and their relative comparisons (**f**) in the ileal samples collected at 60 min time point after an oral gavage in 3 month-old (3 mo) and 26 month-old (26 mo) B6 female mice (n=4 mice each for PBS and NMN, analyzed by unpaired two-sided *t*-test; **e,** \*\*p=0.0033; **f,** \*\*p=0.0066 \*\*\*\* p\<0.0001). **g,** NAD^+^ levels in the ilea of 2 and 24 month-old control and intestinal *Slc12a8* KD B6 female mice (n=6 mice each for 2 month-old control and intestinal *Slc12a8*-KD B6 female mice, and n=9 mice each for 24 month-old control and intestinal *Slc12a8* KD B6 female mice; analyzed by unpaired two-sided *t*-test, \*p=0.0496). All values are presented as mean ± SEM.](nihms-1511128-f0004){#F4}
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